

PRESS RELEASE**STALLERGENES STRENGTHENS ITS BOARD OF DIRECTORS
WITH THE APPOINTMENT OF 3 NEW MEMBERS:****JEAN-LUC BELINGARD, GABRIELA CAMBONI, PATRICK LANGLOIS****Antony, France; 30 May 2011 – 8am**

Stallergenes S.A, a European biopharmaceutical laboratory specialised in the treatment of severe respiratory allergies, strengthened its Board of Directors at its Combined General Meeting, held on 27 May 2011, with the appointment of three new members: Gabriella Camboni, Jean-Luc Bélingard and Patrick Langlois.

These appointments are consistent with the Group's development strategy in its pharmaceutical specialty and, owing to the recognised experience of its new directors, will provide Stallergenes with complementary expertise in this field, at the same time as increasing both female and independent representation on the Board.

Jean-Luc Bélingard

Jean-Luc Bélingard, 62 year-old, is a graduate of HEC and holds an MBA from the University of Cornell (USA). He has more than 36 years of experience in the pharmaceutical industry, in particular with Merck & Co and Roche, where he was a member of the Executive Committee and Chief Executive Officer of Roche Diagnostic. In 1999, Jean-Luc Bélingard joined the Pierre Fabre Group as Chief Executive Officer and Vice-Chairman of the Board of Directors. From January 2002, Jean-Luc Bélingard served as Chairman and Chief Executive Officer of Ipsen Group, a worldwide innovation pharmaceutical group, operating in several specialised therapeutic fields (oncology, neurology, endocrinology and haematology). Since 1 January 2011, Jean-Luc Bélingard has been Chairman and Chief Executive Officer of BioMérieux.

Maria Gabriella Camboni

Maria Gabriella Camboni currently serves as Chief Operating Officer of EOS, a start-up company she co-founded in Milan devoted to translational research in oncology. She previously held various positions in the pharmaceutical industry, including Clinical Project Leader at Sandoz (subsequently Novartis), Head of Clinical Oncology at Boehringer Mannheim, Head of Development for Novuspharma (now Cell Therapeutics), and most recently, Head of Medical Affairs Europe for Novartis Oncology. Gabriella obtained an MD from the University of Milan and specialised in gastroenterology and clinical pharmacology.

Patrick Langlois

Patrick Langlois has more than 30 years experience at a global level for companies and markets in the healthcare sector.

Since 2005, he has been the General Partner at PJJ Conseils Eurl in Paris, a consulting company for healthcare industry, portfolio strategy, corporate development, M & A and financing. He is also a Board member of several pharmaceutical companies in France and abroad. Before creating PJJ Conseils, he served as Group Executive Vice President and CFO of Aventis S.A. (merger of Rhône-Poulenc and Hoechst) in France. He was appointed Vice Chairman of the Management Board in May 2002. Previously he held positions in finance, corporate development and supervising dermatology, protein therapeutics and animal health businesses for the Group in France, Canada and the US. Patrick graduated in Higher Banking Studies and holds a Ph. D in Economics from the University of Rennes.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical laboratory specialising in treatments by allergenic immunotherapy for the prevention and treatment of allergy-related respiratory conditions, such as severe rhino conjunctivitis, rhinitis and allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates nearly 20% (gross) of its sales to its Research and Development activities, which are primarily directed at developing a new therapeutic range: sublingual immunotherapy tablets.

Stallergenes realised 2010 sales of € 216 million, with over 500,000 patients treated with Stallergenes products.

Euronext Paris (Compartment B)

SBF 120.

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP



For further financial information, please visit our website: <http://www.stallergenes.com>

Contacts

Albert Saporta, Chairman and CEO

Tel. +33 1 55 59 20 04

Christian Thiry, Chief Financial Officer

Tel. +33 1 55 59 20 95

e-mail: investorrelations@stallergenes.fr

Investor and Analyst Relations

Lucile de Fraguier, Pavie Finance

Tel. +33 1 42 15 04 39

e-mail: contact@pavie-finance.com

Stallergenes Press Relations

Lise Lemonnier, Senior Communications Director

Tel. + 33 1 55 59 20 96

e-mail: llemonnier@stallergenes.fr